Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma

Effect of an Early Therapeutic Permutation on the Tumoral Control of Patients Receiving in First Line a Specific Inhibitor of Tyrosin Kinase of EGFR (Erlotinib) or a Taxan-based Chemotherapy for the Treatment of Not Resecable Adenocarcinoma With Bronchiolo-alveolar.

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00384826

Enrollment

133

Registered

2006-10-06

Start date

2006-09-30

Completion date

2014-02-28

Last updated

2015-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma, Bronchiolo-Alveolar

Keywords

Adenocarcinoma, Bronchiolo-Alveolar

Brief summary

To evaluate among patients with untreated advanced ADC-CBA, impact on the disease control rate after 4 months treatment of an early therapeutic permutation with the first month in the absence of stabilization or objective answer.

Interventions

DRUGerlotinib

Erlotinib 150 mg/day (until progression)

DRUGpaclitaxel + carboplatine

Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* CBA histologically proven (or cytologically with pneumonic presentation) PS \< 3 signed and written informed consent

Exclusion criteria

* visible tumoral lesion in bronchial fibroscopy

Design outcomes

Primary

Measure	Time frame
16-week Disease Control Rate	4-week

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026